Food Chemistry Advances,
Journal Year:
2022,
Volume and Issue:
1, P. 100023 - 100023
Published: March 2, 2022
The
World
Health
Organization
(WHO)
declared
COVID-19
as
a
pandemic
on
March
11,
2020,
because
of
its
widespread
transmission
and
infection
rates.
unique
severe
disease
was
found
in
Wuhan,
China,
since
December
2019,
swiftly
spread
throughout
the
world.
Natural
chemicals
derived
from
herbal
medicines
medicinal
mushrooms
provide
significant
resource
for
development
novel
antiviral
drugs.
Many
natural
drugs
have
been
proven
to
properties
against
variety
virus
strains,
such
coronavirus
herpes
simplex
(HSV)..
In
this
research,
successful
dietary
treatments
different
COVID
illnesses
were
compared
potential
mushroom
products
therapy.
Google
Scholar,
Science
Direct,
PubMed,
Scopus,
search
keywords
like
COVID,
COVID-19,
SARS,
MERS,
mushrooms,
their
compounds
utilized.
review
literature
we
foucsed
popular
Agaricus
subrufescens
Peck,
blazei
Murill,
Cordyceps
sinensis
(Berk.)
Sacc.,
Ganoderma
lucidum
(Curtis.)
P.
Karst.,
Grifola
frondosa
(Dicks.)
Gray,
Hericium
erinaceus
(Bull.)
Pers.,
Inonotus
obliquus
(Arch.
Ex
Pers.)
Pilát.,
Lentinula
edodes
Pegler,
Pleurotus
ostreatus
(Jacq.)
Kumm.,
Poria
cocos
F.A.
Wolf,
Trametes
versicolor
(L.)
Lloyd.,.
Changed
forms
β-Glucan
seem
good
impact
viral
replication
suppression
might
be
used
future
studies.
However,
results
seems
terpenoids,
lectins,
glycoproteins,
lentinan,
galactomannan,
polysaccharides
are
promising
prophylactic
or
therapeutic
agents
COVID-19.
Journal of Global Health,
Journal Year:
2023,
Volume and Issue:
13
Published: Jan. 13, 2023
Abstract
Background
Safe
and
effective
vaccination
is
considered
to
be
the
most
critical
strategy
fight
coronavirus
disease
2019
(COVID-19),
leading
individual
herd
immunity
protection.
We
aimed
systematically
review
economic
evaluation
of
COVID-19
globally.
Methods
performed
a
systematic
search
identify
relevant
studies
in
two
major
databases
(MEDLINE/PubMed
EBSCO)
published
until
September
8,
2022.
After
deduplication,
researchers
independently
screened
study
titles
abstracts
according
pre-determined
inclusion
exclusion
criteria.
The
remaining
full-text
were
assessed
for
eligibility.
their
quality
reporting
using
Consolidated
Health
Economic
Evaluation
Reporting
Standards
(CHEERS)
2022
checklist
summarized
narratively
presented
results.
Results
identified
25
that
worldwide
by
considering
several
input
parameters,
including
vaccine
cost,
efficacy,
utility
value,
size
targeted
population.
All
suggested
was
cost-effective
or
cost-saving
intervention
mitigating
transmission
its
effect
many
countries
within
certain
conditions.
Most
reported
efficacy
values
ranging
from
65%
75%.
Conclusions
Given
favorable
cost-effectiveness
profile
vaccines
disparities
affordability
across
countries,
prioritization
has
become
paramount.
This
provides
comprehensive
insights
into
will
useful
policymakers,
particularly
highlighting
preventive
measures
preparedness
plans
next
possible
pandemic.
Biomolecules,
Journal Year:
2024,
Volume and Issue:
14(7), P. 797 - 797
Published: July 4, 2024
The
main
protease
(Mpro)
of
SARS-CoV-2
is
an
essential
enzyme
that
plays
a
critical
part
in
the
virus’s
life
cycle,
making
it
significant
target
for
developing
antiviral
drugs.
inhibition
Mpro
has
emerged
as
promising
approach
therapeutic
agents
to
treat
COVID-19.
This
review
explores
structure
protein
and
analyzes
progress
made
understanding
protein–ligand
interactions
inhibitors.
It
focuses
on
binding
kinetics,
origin,
chemical
these
provides
in-depth
analysis
recent
clinical
trials
involving
covalent
non-covalent
inhibitors
emerging
dual
targeting
Mpro.
By
integrating
findings
from
literature
ongoing
trials,
this
captures
current
state
research
into
inhibitors,
offering
comprehensive
challenges
directions
their
future
development
anti-coronavirus
agents.
information
new
insights
inspiration
medicinal
chemists,
paving
way
more
effective
novel
COVID-19
therapies.
The Journal of Clinical Endocrinology & Metabolism,
Journal Year:
2022,
Volume and Issue:
107(7), P. 1799 - 1811
Published: March 9, 2022
Abstract
Obesity
is
associated
with
an
increase
in
morbidity
and
mortality
from
coronavirus
disease
2019
(COVID-19).
The
risk
related
to
the
cytokine
storm,
a
major
contributor
multiorgan
failure
pathological
character
of
COVID-19
patients
obesity.
While
exact
cause
storm
remains
elusive,
disorders
energy
metabolism
has
provided
insights
into
mechanism.
Emerging
data
suggest
that
adipose
tissue
obesity
contributes
several
ways.
First,
restricts
pulmonary
function
by
generation
mechanical
pressures
promote
systemic
hypoxia.
Second,
supplies
base
for
severe
acute
respiratory
syndrome
2
entry
overexpression
viral
receptors
[angiotensin-converting
enzyme
dipeptidyl
peptidase
4].
Third,
impaired
antiviral
responses
adipocytes
immune
cells
result
dysfunction
immunologic
surveillance
as
well
clearance
systems.
Fourth,
chronic
inflammation
secreting
more
proinflammatory
cytokines.
Fifth,
abnormal
levels
adipokines
hyperimmune
response
virus
lungs
other
organs
enhance
storm.
Mitochondrial
adipocytes,
cells,
cell
types
(endothelial
platelets,
etc)
common
cellular
mechanism
development
which
leads
progression
mild
cases
high
mortality.
Correction
surplus
through
various
approaches
recommended
prevention
treatment
obese
patients.
Biomedicine & Pharmacotherapy,
Journal Year:
2022,
Volume and Issue:
147, P. 112700 - 112700
Published: Feb. 4, 2022
Coronavirus
disease
2019
(COVID-19)
represents
an
unmet
clinical
need,
due
to
a
high
mortality
rate,
rapid
mutation
rate
in
the
virus,
increased
chances
of
reinfection,
lack
effectiveness
repurposed
drugs
and
economic
damage.
COVID-19
pandemic
has
created
urgent
need
for
effective
molecules.
Clinically
proven
efficacy
safety
profiles
have
made
favipiravir
(FVP)
remdesivir
(RDV)
promising
therapeutic
options
use
against
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
infection.
Even
though
both
are
prodrug
molecules
with
antiviral
role
based
on
similar
mechanism
action,
differences
pharmacological,
pharmacokinetic
pharmacotoxicological
mechanisms
been
identified.
The
present
study
aims
provide
comprehensive
comparative
assessment
FVP
RDV
SARS-CoV-2
infections,
by
centralizing
medical
data
provided
significant
literature
authorized
trials,
focusing
importance
better
understanding
interactions
between
drug
infectious
agents
order
improve
global
management
patients
reduce
risk
resistance.
ACS Medicinal Chemistry Letters,
Journal Year:
2023,
Volume and Issue:
14(6), P. 757 - 765
Published: May 11, 2023
Targeting
structured
RNA
elements
in
the
SARS-CoV-2
viral
genome
with
small
molecules
is
an
attractive
strategy
for
pharmacological
control
over
replication.
In
this
work,
we
report
discovery
of
that
target
frameshifting
element
(FSE)
using
high-throughput
small-molecule
microarray
(SMM)
screening.
A
new
class
aminoquinazoline
ligands
FSE
are
synthesized
and
characterized
multiple
orthogonal
biophysical
assays
structure–activity
relationship
(SAR)
studies.
This
work
reveals
compounds
mid-micromolar
binding
affinity
(KD
=
60
±
6
μM)
to
supports
a
mode
distinct
from
previously
reported
binders
MTDB
merafloxacin.
addition,
active
vitro
dual-luciferase
in-cell
dual-fluorescent-reporter
assays,
highlighting
promise
targeting
RNAs
druglike
alter
expression
proteins.
Journal of Genetic Engineering and Biotechnology,
Journal Year:
2022,
Volume and Issue:
20(1), P. 78 - 78
Published: May 24, 2022
COVID-19
is
an
illness
caused
by
severe
acute
respiratory
syndrome
coronavirus
2.
Due
to
its
rapid
spread,
in
March
2020
the
World
Health
Organization
(WHO)
declared
pandemic.
Since
outbreak
of
pandemic
many
governments,
scientists,
and
institutions
started
work
on
new
vaccines
finding
repurposing
drugs.
Drug
excellent
option
for
discovery
already
used
drugs,
effective
against
COVID-19,
lowering
cost
production,
shortening
period
delivery,
especially
when
preclinical
safety
studies
have
been
performed.
There
are
approved
drugs
that
showed
significant
results
like
ivermectin
hydrochloroquine,
including
alternative
treatment
options
utilizing
herbal
medicine.
Viruses,
Journal Year:
2023,
Volume and Issue:
15(3), P. 811 - 811
Published: March 22, 2023
Molnupiravir
(MOV)
and
nirmatrelvir/ritonavir
(NMV/r)
are
efficacious
oral
antiviral
agents
for
patients
with
the
2019
coronavirus
(COVID-19).
However,
little
is
known
about
their
effectiveness
in
older
adults
those
at
high
risk
of
disease
progression.
This
retrospective
single-center
observational
study
assessed
compared
outcomes
COVID-19
treated
MOV
NMV/r
a
real-world
community
setting.
We
included
confirmed
combined
one
or
more
factors
progression
from
June
to
October
2022.
Of
283
patients,
79.9%
received
20.1%
NMV/r.
The
mean
patient
age
was
71.7
years,
56.5%
were
men,
71.7%
had
≥3
doses
vaccine.
COVID-19-related
hospitalization
(2.8%
3.5%,
respectively;
p
=
0.978)
death
(0.4%
0.104)
did
not
differ
significantly
between
groups.
incidence
adverse
events
2.7%
5.3%,
treatment
discontinuation
5.3%
groups,
respectively.
similar
among
low.
